Search Results for “research” – Page 306 – media

How to Write a Development Letter to Clients after an Exhibition

After attending Shanghai CNEF and Hospitalar in Brazil you come home and look at the pile of name cards and the masses of client information you collected. Now what? We often establish new business relationships at exhibitions such as these but the key of securing them lies in how you follow up on your clients. Ddu (www.drugdu.com), the leading global pharmaceutical and medical device B2B online platform, today shares with you some insight on how to organize client materials and write your first follow up development letter. I. Organize and follow up on your clients with purpose The first step is to collect as much information as possible and pay special attention to all the relevant details at the exhibition. For example, what the client is looking for, what they are most concerned about, what kind of products and suppliers they have in mind and which business partners they would like to keep. After this you will be able to arrange the information according to clients’ interests ...
- Source: Ddu
- 892
- September 18, 2017
Ddu College development letter
Cancer Startup Torque Therapeutics Nabs $21 Million and Sets Up Shop in Kendall Square

Torque Therapeutics has come out of stealth mode to launch with a $21 million Series A financing. It is looking to raise another $14 million, according to its filing with the U.S. Securities and Exchange Commission (SEC).
- Source: Biospace
- 823
- September 15, 2017
cell immune Series therapy
China’s Import and Export Report of Surgical Instruments

According to a global statistics report on medical devices, the global surgical instruments market has witnessed a drastic growth spurt in the past 8 years. In 2010, global sales of surgical instruments reached 12 billion USD, 12.9 billion USD in 2011 and 18.6 billion USD in 2014.
- Source: Ddu
- 2,995
- September 15, 2017
export import Market Reports surgical
FDA grants fast-track designation for Shire’s lung drug

The FDA has granted Fast Track designation to Shire's SHP607 for the prevention of chronic lung disease in extremely premature infants.
- Source: Pharmatimes
- 582
- September 14, 2017
chronic Clinical lung New Approvals
Apple is testing whether the Apple Watch can detect heart problems

Apple is working with partners to test whether its smartwatch can be used to detect common heart conditions, an effort that would make its device a "must have" for millions of people worldwide. The company is partnering up with a group of clinicians at Stanford, as well as telemedicine vendor American Well, to test whether Apple Watch's heart rate sensor can detect abnormal heart rhythms in a cohort of patients, according to two people familiar. The people requested anonymity as these plans have not yet been made public.
- Source: finance.yahoo
- 832
- September 14, 2017
abnormal heart rhythm Arrhythmias Company Insight
Boehringer collaborates with Gubra to develop next generation obesity treatments

Germany based Boehringer Ingelheim has committed up to €250 million ($300 million) to work with Gubra on obesity treatments. As per the deal, Boehringer can access Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.
- Source: Biospectrumasia
- 486
- September 14, 2017
cardiometabolic Market Views obesity
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market

After committing billions of dollars to a new hepatitis C cocktail that had the potential to compete with the already deeply entrenched rivals on the market, J&J is calling it quits.
- Source: endpts
- 465
- September 12, 2017
hepatitis Market Views
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise

Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose technology targets the retinoic acid-inducible gene I (RIG-I) pathway.
- Source: genengnews
- 542
- September 11, 2017
acquisition immunotherapy Market Views RIG-I
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled for 8:30 AM EDT this morning; dial-in and webcast details are provided below.
- Source: Globenewswire
- 3,273
- September 11, 2017
cancer Company Insight T-cell
Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Source: Spjnews
- 745
- September 8, 2017
cancer Clinical Trials CLL inhibitor SLL

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.